Adverse Drug Event: Clinical Trials

5 trials for Adverse Drug Event, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting, 1 unknown. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 2, Recruiting 2, Unknown 1
Phase 22Completed 1, Unknown 1

Follow Adverse Drug Event: new trials by email Literature Review of Adverse Drug Event trials Research Report on Adverse Drug Event

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of GC101 TIL in Advanced Melanoma (BZ)
GC101 TIL - Tumor Infiltrating Lymphocytes, Safety
Phase 1 / Phase 2CompletedShanghai Juncell Therapeutics182023-11-082025-12-23
Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
Ad-TD-nsIL12 - Oncolytic Virus, Diffuse Intrinsic Pontine Glioma
Phase 1RecruitingCapital Medical University182023-01-042024-02-28
Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
Ad-TD-nsIL12 - Oncolytic Virus, Diffuse Intrinsic Pontine Glioma
Phase 1RecruitingCapital Medical University182023-01-042024-02-28
A Phase I Study of GC101 TIL in Advanced Solid Tumors
TIL therapy - Tumor Infiltrating Lymphocytes, Safety
Phase 1CompletedShanghai Juncell Therapeutics432022-10-122025-12-10
TIL and Anti-PD1 in Metastatic Melanoma
Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha - Toxicity, Drug, Adverse Drug Event
Phase 1 / Phase 2UnknownLeiden University342018-07-312023-12-12

Narrower conditions

Drug-Related Side Effects and Adverse Reactions (5)  ·  Diffuse Intrinsic Pontine Glioma (2)  ·  Melanoma (2)

Broader conditions

Chemically-Induced Disorders (5)  ·  Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms by Site (4)  ·  Neoplasms, Germ Cell and Embryonal (4)  ·  Neoplasms, Nerve Tissue (4)  ·  Neuroectodermal Tumors (4)  ·  Brain Diseases (2)  ·  Brain Neoplasms (2)  ·  Brain Stem Neoplasms (2)  ·  Central Nervous System Diseases (2)  ·  Central Nervous System Neoplasms (2)  ·  Glioma (2)  ·  Infratentorial Neoplasms (2)  ·  Neoplasms, Glandular and Epithelial (2)

Interventions

Nivolumab (1)

Sponsors

Capital Medical University (2)  ·  Shanghai Juncell Therapeutics (2)  ·  Leiden University (1)

Countries

China (4)  ·  Netherlands (1)

Top investigators

Hongwei Zhang, Prof. (2)  ·  Ellen Kapiteijn, Dr. (1)  ·  Jun Guo (1)

Results publications

PMID 19223865, PMID 29123084, PMID 33182528, PMID 33234662